Ebselen reduces nitration and restores voltage-gated potassium channel function in small coronary arteries of

Aaron H Bubolz1, Qingping Wu, Brandon T Larsen

  • 1Department of Medicine, The Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Insights

Diabetic rats show impaired small coronary artery function due to peroxynitrite (ONOO(-)) damaging potassium channels. Ebselen treatment improved function, suggesting a therapeutic role for vascular complications in diabetes mellitus.

Area of Science:

  • Cardiovascular Research
  • Diabetology
  • Molecular Pharmacology

Background:

  • Diabetic small coronary arteries (SCA) display increased peroxynitrite (ONOO(-)) and impaired voltage-dependent potassium (K(v)) channel function.
  • The direct role of ONOO(-) in K(v) channel dysfunction in diabetes remains unclear.

Purpose of the Study:

  • To investigate if ONOO(-) causes K(v) channel impairment in diabetic rat coronary smooth muscle cells (SMC) via tyrosine nitration.
  • To evaluate the therapeutic potential of ebselen (Eb) in mitigating these diabetes-induced vascular changes.

Main Methods:

  • Diabetic and control rats were treated with or without ebselen.
  • Techniques included immunohistochemistry (IHC), immunoprecipitation (IP), Western blot (WB), videomicroscopy, and patch-clamp analysis.
  • Analysis focused on ONOO(-) levels, K(v)1.2 subunit nitration and expression, and vascular responses to forskolin.

Main Results:

  • Diabetic rats exhibited elevated ONOO(-) and K(v)1.2 alpha-subunit nitration, with reduced K(v)1.2 expression in SCA.
  • Ebselen treatment ameliorated these changes.
  • Impaired vasodilation to forskolin in diabetic rats was partially restored by ebselen, indicating improved K(v)1 channel function.

Conclusions:

  • Enhanced nitrosative stress contributes to K(v)1 channel dysfunction in the coronary microcirculation of diabetes mellitus.
  • Ebselen shows promise as a therapeutic agent for diabetic vascular complications.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...